Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S1QN
|
|||
| Drug Name |
Anti-CEA-CAR T
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [1] | |
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 1 | [1] | ||
| Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 1 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1 | [1] | ||
| Company |
Southwest Hospital, China
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | CAR-T-Cell-Therapy | [1] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.